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Abstract
There presently is no rapid method to assess the bactericidal activity of new regimens for tuberculosis. This study examined
PNU-100480, TMC207, PA-824, SQ109, and pyrazinamide, singly and in various combinations, against intracellular M.
tuberculosis, using whole blood culture (WBA). The addition of 1,25-dihydroxy vitamin D facilitated detection of the activity
of TMC207 in the 3-day cultures. Pyrazinamide failed to show significant activity against a PZA-resistant strain (M. bovis BCG),
and was not further considered. Low, mid, and high therapeutic concentrations of each remaining drug were tested
individually and in a paired checkerboard fashion. Observed bactericidal activity was compared to that predicted by the
sum of the effects of individual drugs. Combinations of PNU-100480, TMC207, and SQ109 were fully additive, whereas those
including PA-824 were less than additive or antagonistic. The cumulative activities of 2, 3, and 4 drug combinations were
predicted based on the observed concentration-activity relationship, published pharmacokinetic data, and, for PNU-100480,
published WBA data after oral dosing. The most active regimens, including PNU-100480, TMC207, and SQ109, were
predicted to have cumulative activity comparable to standard TB therapy. Further testing of regimens including these
compounds is warranted. Measurement of whole blood bactericidal activity can accelerate the development of novel TB
regimens.
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Introduction
New drugs and regimens are urgently needed that can shorten
the required duration of tuberculosis treatment. This need is
greatest for extensively-drug resistant disease (XDR-TB), which
presently requires at least 24 months of treatment for cure [1]. The
requirement for prolonged therapy arises due to the persistence of
dormant or semi-dormant mycobacteria that exhibit phenotypic
drug tolerance [2]. Such subpopulations can arise solely by
chance; however, their numbers are greatly amplified in response
to oxygen or nutrient starvation in vitro, or to pressure from host
immune mechanisms in vivo.
The problem of microbial persistence due to phenotypic
tolerance is not unique to mycobacteria [3]. In streptococcal and
enterococcal endocarditis, small numbers of bacteria can similarly
persist and cause relapse unrelated to the acquisition of new drug
resistance. Specific drug combinations – b-lactams plus aminogly-
cosides– increasethelikelihood ofendocarditiscureandshortenthe
required duration of treatment [4]. The goal of the present study
was to identify similarly favorable new drug combinations for
tuberculosis.
Current strategies to test new TB drug combinations have
important shortcomings. MIC testing, a common first step, does not
adequately predict bactericidal activity for TB drugs, even when
comparisons are limited to drugs within a single class [5]. Short term
studies in the mouse model, a common next step of testing, do not
adequately predict sterilizing capacity [6]. This project instead used
whole blood culture to rapidly examine the potential activity of new
regimens. Mycobacteria added to heparinized blood are quickly
ingested by phagocytic cells, first by neutrophils and subsequently by
monocytes [7,8]. Expression of host effector mechanisms results in
inhibition of mycobacterial growth.The extentofinhibition depends
on strain virulence and donor immune status [7,9], being greater in
tuberculin skin test positive donors or following vaccination with M.
bovis Bacillus Calmette-Gue ´rin (BCG), and reaching bacteriostasis in
TB patients tested with their own isolates [10].
Several studies have examined the whole blood bactericidal
activity (WBA) of TB drugs at multiple time points after oral drug
administration. First line drugs show a rank order of cumu-
lative WBA (its area under the curve [AUC] over 24 hrs) of
rifampin.isoniazid.pyrazinamide.ethambutol when tested in
healthy volunteers [8]. Current regimens for multi-drug resistant
(MDR) disease are less active than standard therapy [11]. In one
study of patients with drug-sensitive TB, cumulative WBA was
greater during the intensive phase of standard therapy, correlated
with the rate of decline of sputum log colony counts, and was
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e30479superior in patients whose sputum cultures converted to negative
after 8 weeks of treatment [10]. WBA may therefore be described as
an emerging biomarker for TB treatment. Its predictive value may
in part arise due to its ability to model drug effects against semi-
dormant mycobacteria in the context of a bacteriostatic host
immune response.
Methods
A single healthy volunteer served as a blood donor for this
study, after providing written informed consent. The study
protocol was approved by the Institutional Review Board of the
Veterans Administration Connecticut Healthcare System. Drug
powders were either dissolved first in dimethylsulfoxide (PNU-
100480 [sutezolid], PA-824, TMC207 [bedaquiline], and SQ109),
or RPMI-1640 tissue culture medium (isoniazid, rifampin, and
pyrazinamide). Stock solutions were prepared at concentrations
ranging from 10 mg/L (isoniazid) to 200 mg/L (pyrazinamide)
and kept at 230uC until needed. WBA was measured as
previously described [12] with exceptions as noted below. Briefly,
M. tuberculosis H37Rv was grown in mycobacterial growth
indicator tubes (MGIT, Becton-Dickinson) until 1–2 days after
growth was detected, and frozen in aliquots. A titration
experiment determined the relationship between inoculum size
and time-to-positivity (TTP) over a 6-log range (500 ml to 0.005 ml,
figure 1) using a MGIT 960 detection system, and identified the
volume positive in 5.5 days. Whole blood cultures were conducted
in sealed screw-top tubes with slow constant rotation. The cultures
consisted of 300 ml heparinized blood, an equal volume of RPMI
1640 tissue culture medium, and the specified volume of
mycobacterial stock. After 72 hrs, cells were sedimented, the
liquid phase removed, and blood cells disrupted by hypotonic lysis.
Bacilli were recovered, resuspended in 7H9 broth, and inoculated
into MGIT. Days and hours until cultures were detected as
positive were recorded. All cultures were performed in duplicate;
TTP values were represented as the mean of duplicate cultures.
Log change in viability was calculated as log(final) – log(initial),
where final and initial are the volumes corresponding to TTP of the
completed cultures and its inoculum, respectively, based on the
titration curve. The laboratory protocol and software (version 12)
developed by the author (RSW) are available on request. WBA
was reported as log change/day.
Each drug was tested individually to establish its concentration –
activity relationship. Drug pairs were then tested in a checker-
board fashion (figure 2). The observed activity of each drug pair
was compared to that predicted by their sum when tested
separately. The mean difference between observed and expected
values for the full range of expected therapeutic concentrations
was then calculated for each drug pair.
Drug activity after oral administration was predicted based on
published PK data and the observed concentration-activity
relationship (figure 3). For PA-824, mean values of 3 experiments
were used. Drug concentrations in vivo are twice those in ex vivo
whole blood culture, due to dilution with tissue culture medium.
Expected concentrations in plasma of the novel compounds were
therefore reduced by half so that results could be compared to
orally-administered therapies. Values for hourly time points were
estimated by interpolation. The combined activities of specific
drug combinations were calculated for each hourly time point by
adding the activities of the individual drugs and adjusting the result
according to the mean difference between observed and predicted
values. Cumulative WBA was then calculated as the AUC0–24 by
the trapezoidal method, and reported as log change.
Paired values were compared using the paired t test.
Comparisons among multiple values were performed by the
repeated measures one-way analysis of variance (ANOVA). Post-
hoc testing to examine differences between specific pairs was then
performed by the Holm-Sidak method. All statistical tests were
performed using SigmaPlot version 11.
Results
Preliminary experiments addressed 3 concerns of this project: the
method of determining the titration curve, the suitability of whole
blood culture conditions to detect effects of TMC207 (bedaquiline),
and the activity of pyrazinamide against pyrazinamide-resistant
mycobacteria. Initial experiments had indicated that the time-to-
positivity of MGIT cultures from highly bactericidal drug com-
binationscouldexceedthosetested inthetitrationexperiment.Such
results cannot be analyzed by point-to-point interpolation, the
method used in previous studies of this method. The WBA
spreadsheet was therefore modified to perform exponential
regression analysis rather than interpolation, using the equation
y=y0+ae
2bx for curve fitting, where y=time-to-positivity in days,
Figure 1. Effects of substituting regression analysis for point-to-point interpolation in calculating D log CFU from time to positivity
(TTP) in mycobacterial growth indicator tubes (MGIT). The left panel indicates the accuracy of curve fitting (the relationship between
observed and predicted values). The right panel compares the results of the two methods (regression vs. interpolation).
doi:10.1371/journal.pone.0030479.g001
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y0, a, and b that most closely fit experimental results were identified
using the iterative non-linear regression module (Solver) provided
with Microsoft Excel, using its default parameters. This exponential
decay equation was selected because it provided the best fit for all of
5 different batches of M. tuberculosis stock (not shown).The adequacy
of curve fitting for the batch used in this study is illustrated by the
superimposition of curves for predicted and observed data in the left
Figure 2. Bactericidal activities of 2 and 3-drug combinations against intracellular M. tuberculosis in whole blood culture. Negative
values in these blocks indicate killing. A color gradient has been applied to indicate green as bacterial growth, and red as death. The difference from
sum was determined by subtracting the activity predicted as the sum of both compounds tested individually from that observed when tested in
combination. Positive values here indicate combinations less active than predicted. TMC207 and SQ109 showed additive activity when combined
with PNU-100480. Combinations of PA-824 with either PNU-100480 or TMC207, or as a 3-drug combination, were less than additive.
doi:10.1371/journal.pone.0030479.g002
Figure 3. Process for calculating cumulative whole blood bactericidal activity (WBA) of drug combinations.
doi:10.1371/journal.pone.0030479.g003
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obtained using the two methods (regression vs. interpolation). The
two sets of results are equal except for those samples showing
maximal bactericidal effect, the activities of which were underes-
timated by the interpolation method. The exponential regression
method was therefore selected for use in this study.
A second preliminary experiment sought to identify whole blood
culture conditions that adequately detected the effect of TMC207
(bedaquiline). This compound, which acts by selective inhibition of
mycobacterial ATP synthetase [13], has a delayed time to onset in
vivo and in vitro that presumably reflects the size of the ATP pool at
the start of drug exposure and the net balance between ATP
consumption and production. Studies in patients treated with
TMC207 indicate a 4-day delay before an effect on mycobacterial
viability in sputum becomes evident [14]. Shorter times to onset of
action of TMC207 have been reported under hypoxic conditions
[15] and in intracellular infection [16] as compared to aerobic
broth culture. However, no previous studies have examined the
effects of TMC207 in cell culture infection models of 3-day
duration. Mammalian cell viability in the sealed whole blood
cultures is limited by progressive depletion of oxygen and
nutrients. We therefore tested conditions with different head space
volumes and culture durations to determine effects on drug activity
(table 1). We included cultures in which 15 nM 1,25-dihydroxy
vitamin D was added, based on the hypothesis that stresses due to
activation of cellular anti-mycobacterial mechanisms by vitamin D
[17] might in turn accelerate mycobacterial ATP consumption
and thereby hasten onset of drug action. Negative values in table 1
indicate bactericidal activity. The addition of vitamin D indeed
enhanced our ability to detect the effect of TMC207 without
requiring changes in whole blood culture tube geometry or
duration. The vitamin D concentration was insufficient to have a
direct effect on M. tuberculosis viability. All subsequent experiments
were therefore conducted in the presence of added vitamin D.
A final preliminary experiment examined the activity of
pyrazinamide-containing regimens against PZA-resistant M. bovis
BCG (ATTC TMC 1101). Although pyrazinamide has historically
been a key sterilizing TB drug, recent surveys indicate resistance
rates as high as 85% in MDR-TB strains [18]. PZA is often
empirically included in regimens for M/XDR-TB, due to
uncertainties as to optimal methods for resistance testing. One
study has suggested that pyrazinamide may act at least in part via
a host cellular target [19], thus casting doubt on the significance of
microbial pyrazinamide resistance. M. bovis strains (including
BCG) are characteristically resistant to pyrazinamide [20]. Unlike
M. tuberculosis, which grew in the absence of added drug, viability
of the attenuated BCG strain declined by log 20.135. Progressive
addition of vitamin D, PNU-100480, and PZA (20 mg/L) resulted
in progressive loss of viability, to log 20.151, 20.372, and
20.410, indicating a net incremental effect of pyrazinamide of
20.038. The effect of pyrazinamide appeared substantially
reduced compared that when tested against M. tuberculosis
following oral administration (mean, 20.1006.065) [12]. Given
the widespread reports of PZA-resistance in M/XDR-TB, and our
inability to show strong activity against PZA-resistant strains,
pyrazinamide was not considered further for inclusion in
candidate regimens against XDR-TB.
The bactericidal activities of drugs tested individually and in 2
and 3-way combinations areshown infigure 2.Drug concentrations
were selected to approximately reflect low, mid, and high
therapeutic plasma concentrations following oral dosing
[12,14,21]. A color gradient has been applied across all cells to
indicate green as bacterial growth, and red as death. The activities
of individual compounds appear in the first column and row of each
checkerboard. When tested individually, the activities of TMC207
and SQ109 increased progressively with increasing drug concen-
tration. This was not the case for either PNU-100480 (sutezolid) or
PA-824, which showed no further increase in activity as
concentrations increased from mid to high therapeutic levels.
Within the range of tested concentrations, PNU-100480 was the
most active single drug, differing from the others by one way
repeated measures ANOVA (P=.004) and post-hoc analysis
(Holm-Sidak method).
Cells other than those in the first column and row in figure 2
indicate the combined effects of multi-drug combinations. The
combinations differed significantly by one way repeated measures
ANOVA (P,.001). PNU-100480 plus TMC207 was the most
active combination, and PA-824 plus TMC207, the least.
For each combination, the observed activity was compared to
that expected as the sum of each drug tested individually. The
mean and standard deviation of the difference between observed
and expected values appears in each panel. Positive values indicate
drug combinations that overall were less than additive, and
negative values, more than additive. No combination was
significantly more than additive. The combinations of PNU-
100480 plus TMC207 (panel A) and PNU-100480 plus SQ109
(panel E) overall were additive, each having observed and
expected values that did not differ significantly. In contrast, the
combination of PA-824 plus TMC207 (panel B) was significantly
less active than expected (mean difference=+.179, P=.027 by
Table 1. Bactericidal activities of TMC207, PNU-1004800, rifampin (RIF), isoniazid (INH), and pyrazinamide (PZA), against










1 mg/L RIF 5 mg/L INH 1 mg/L PZA 20 mg/L
(nM) (days) (ml) D log CFU/d
0 3 0.1/0.4 0.086 0.117 20.745 21.382 20.936 0.048
0 3 1.4/0.6 20.004 0.022 20.652 21.575 20.817 0.195
0 7 1.4/0.6 0.182 0.180 20.299 21.034 20.562 0.143
15 3 0.1/0.4 20.022 20.073 20.864 21.466 20.936 0.009
15 3 1.4/0.6 0.216* 20.327*
Negative values indicate killing.
*Results are carried over from figure 2.
doi:10.1371/journal.pone.0030479.t001
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toward reduced activity overall was present (mean differ-
ence=+.063, P=.284). Panel D shows the predicted and actual
activity of the PNU-TMC-Pa combination. In this case, limited
testing was performed, using only mid concentrations of PNU-
100480 and TMC207. Despite the reduced number of test
conditions, the combination was significantly less active than
predicted (difference=+.494, P=.027). Inspection of individual
cells revealed antagonism when low concentrations of PA-824
were combined with low or mid concentrations of PNU-100480.
Under these conditions, the activity of the two drugs combined
appeared less than that of PNU-100480 alone. Antagonism was
also apparent when low concentrations of PA-824 were combined
with mid concentrations of TMC207 plus PNU-100480.
For 3 of the compounds tested (PNU-100480, TMC207, and
PA-824), knowledge of a compound’s concentration-activity
relationship and pharmacokinetics in plasma should enable the
prediction of its cumulative WBA after oral dosing according to
the method outlined in figure 3. This hypothesis was tested for
PNU-100480 at a dose of 600 mg orally BID, for which both PK
and WBA were previously measured in 7 healthy volunteers [12].
To calculate predicted WBA from in vitro data, drug concentra-
tions in whole blood culture was assumed to be half those in blood,
due to dilution with tissue culture medium. Predicted cumulative
WBA in these subjects (20.36760.065, mean SD) did not differ
significantly from that measured directly (20.31660.044) accord-
ing to paired t test (P=.06). However, the trend toward statistical
significance indicated that cumulative WBA ex vivo might be lower
than that predicted in vitro. We therefore adopted a conservative
approach and used the ex vivo values for PNU-100480 for all
subsequent comparisons. In each case, the activity of a regimen
was predicted as the sum of the individual drugs adjusted by the
mean difference between observed and predicted values for that
combination.
Results for combinations of PNU-100480 and TMC207 are
illustrated in figure 4. Current recommended dosing for TMC207
is 400 mg daily for the first 2 weeks of treatment, followed by
200 mg thrice weekly (TIW) thereafter [14]. Plasma levels of
TMC207 are lower during intermittent treatment. This is reflected
in the reduced cumulative WBA during intermittent vs. daily
dosing, whether given individually, or in combination with PNU-
100480.
Results for other 2, 3, and 4-drug combinations are summarized
in table 2. In the case of SQ109, drug activity in the lung cannot
be directly estimated based on levels in plasma. In the mouse,
SQ109 concentrations in lung are more than 100-fold greater than
those in plasma, reaching concentrations .10-fold above MIC
[22]. The data for SQ109 in table 2 assume a mean effective
concentration of 2 mg/L, 4-fold above MIC. At this concentra-
tion, SQ109 adds cumulative bactericidal activity of log20.14 to
that of PNU-100480. This is consistent with other reports of
favorable interactions of SQ109 with both TMC207 and PNU-
100480 in various in vitro models [23,24]. The combination of
PNU-100480, TMC207, and SQ109 was the most active of those
evaluated. It compared favorably to cumulative WBA reported in
TB patients receiving standard daily therapy, with a value
intermediate to those during the intensive and continuation
phases of treatment [10]. Readers will note that in the 2001 and
2003 publications, WBA was reported as log change over the
entire 3 day period of whole blood culture rather than as log
change per day. Those values have here been reduced by a factor
of 3 for consistency with current methods.
Antagonism was apparent when 200 mg PA-824 was added to
some PNU or TMC-containing regimens. Of the five instances in
table 2 in which 200 mg PA-824 was added to a drug or drug
combination, four were predicted to show antagonism (i.e.,
reduced activity with PA-824 added). At the 600 mg dose, two
of four showed antagonism. The remainder all showed less than
additive effects.
Discussion
This study examined the bactericidal activities of PNU-100480,
TMC207, PA-824, and SQ109, singly and in various combina-
tions, using whole blood culture. These compounds are each
members of new classes of antimycobacterial drugs: oxazolidinone,
diarylquinoline, nitroimidazole, and ethylenediamine, respectively.
None exhibits cross-resistance with existing TB drugs. For each,
MICs against M/XDR-TB strains equal those for fully drug-
sensitive strains. As a result, new regimens comprised of these
drugs will be as active against highly resistant mycobacterial strains
as for drug sensitive strains. This permits experimental studies with
a fully sensitive M. tuberculosis strain such as H37Rv to inform
activity against highly resistant strains [25].
Figure 4. Predicted whole blood bactericidal activity of TMC207 (J, bedaquiline) 400 mg QD and 200 mg TIW, and PNU-100480 (U,
sutezolid) 600 mg BID, singly and together.
doi:10.1371/journal.pone.0030479.g004
Regimens for XDR-TB
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of PNU-100480 and TMC207 were highly active, approaching
the combined activity of isoniazid plus rifampin, whereas 2 and 3-
drug combinations including PA-824 showed less than fully
additive activity. These observations can provide important
guidance in the selection for further testing of novel regimens
against tuberculosis in animal models and in patients. At the same
time, the findings raise questions as to the mechanisms underlying
these observations, and the extent to which in vitro models can
replicate the complexity and variability of human disease.
The range of drug concentrations tested in this study reflected
those in plasma in phase 1 and 2 clinical trials, recognizing that
our understanding of optimal dosing of these drugs may yet be
incomplete. PNU-100480 and PA-824 both have been reported to
show time-dependent killing [12,26]. The finding in the present
study that neither drug showed increased activity as drug
concentrations increased from 1 to 2 mg/L is consistent with time
dependence.ThePK/PD relationshipsof TMC207and SQ109 are
less well understood. In the present study, the activity of TMC207
continued to increase as its concentration increased up to 3 mg/L.
Mean plasma concentrations of TMC207 of 1.77 mg/L have been
reported after 2 weeks of 400 mg QD dosing; these decline to
0.9 mg/L during subsequent 200 mg TIW dosing [27]. Tibotec has
indicated the latter dose was selected to maintain trough plasma
concentrations above 0.6 mg/L. The present findings indicate
higher TMC207 doses may be more efficacious, particularly when
combined with PNU-100480. Additional studies are warranted to
confirm this hypothesis, and to determine the safety of such higher
doses. In the case of SQ109, conclusions must be considered
tentative, as its killing is concentration-dependent, and its con-
centrations in the human lung are not yet known.
PNU-101603, the sulfoxide metabolite of PNU-100480, ap-
peared not to contribute to its parent when the two were combined
in vitro (figure 2); similarly, the observed cumulative WBA of PNU-
100480 after oral dosing was no greater than that predicted in vitro
based solely on concentrations of the parent. Levels of PNU-
101603 reach concentrations in humans several times that of
PNU-100480 [12]. Nonetheless, this finding would appear to
indicate that metabolites of PNU-100480 contribute little if any to
its intracellular mycobactericidal activity.
The finding that combinations of PA-824 with PNU-100480 or
TMC207 were less than additive, and in some circumstances,
antagonistic, was unexpected. Studies in the mouse model of other
drug combinations that include PNU-100480 have not shown
evidence of antagonism [28]. However, a recent study of Tasneen
et al found antagonism when PA-824 was added to the
combination of TMC207 plus pyrazinamide in the mouse model,
resulting in .1 log increases in CFU counts that could not be
explained by drug-drug PK interactions [29]. The basis of these
observations is uncertain. PA-824 appears to act by different
mechanisms depending on the microbial culture conditions [30].
When tested against aerobic, replicating cultures, it interferes with
the synthesis of ketomycolates [31], which are important
components of the mycobacterial cell wall. Structure-functional
analyses of related nitroimidazoles indicate this activity is
unrelated to that exerted against hypoxic, non-replicating cultures,
which instead appears to reflect respiratory poisoning by PA-824-
derived nitric oxide, with subsequent depletion of bacterial ATP
[30]. Combinations of PA-824 and TMC207 may therefore be less
than fully additive under hypoxic conditions, as they share a
common mechanism of action. The mechanism of action of PA-
824 has not been studied under the conditions present in whole
blood culture, which are neither hypoxic nor fully replicating.
Under non-hypoxic conditions, nitric oxide triggers a dormancy
response in M. tuberculosis through activation of DosR [32].
Resulting alterations in replication and biosynthesis may affect the
activity of other drugs such as PNU-100480 and TMC207.
Further research is warranted to test this hypothesis.
These experiments were intended to provide a rapid survey of
potential drug combinations rather than to serve as definitive
experiments. As such, their limitations should be acknowledged.
Studies of antimicrobial activity conducted by adding drugs
directly to cultures eliminate the greatest source of variability, that
of inter-subject differences in pharmacokinetics and metabolism.
Additional population-based studies will be required to better
understand how these PK differences affect the efficacy of new TB
regimens. Three dimensional modeling of drug interactions [33]
may provide a more accurate estimation of their combined effects
than the averaging method used here. Studies of WBA in TB
patients will be required to better understand the contribution of
Table 2. Predicted cumulative whole blood bactericidal
activity of single drugs and multi-drug combinations against
M. tuberculosis, based on published pharmacokinetic data,
and the concentration-activity relationships and drug-drug
pharmacodynamic interactions in figure 2.
Cumulative WBA
Single drugs D log
Pa 200 mg QD 20.09
J 200 mg TIW 20.09
Pa 600 mg QD 20.22
J 400 mg QD 20.21
U 600 mg BID* 20.32
2-drug combinations
Pa 200 mg QD+J 200 mg TIW +0.01
Pa 600 mg QD+J 400 mg QD 20.25
U*+Pa 200 mg QD 20.34
U*+Pa 600 mg QD 20.47
U*+J 200 mg TIW 20.41
U*+J 400 mg QD 20.53
U*+Sq 20.46
3-drug combinations
U*+J 200 mg TIW+Pa 200 mg QD 20.00
U*+J 400 mg QD+Pa 600 mg QD 20.25
U*+Sq+J 200 mg TIW 20.55
U*+Sq+J 400 mg QD 20.67
4-drug combinations
U*+Sq+J 200 mg TIW+Pa 200 mg QD 20.24
U*+Sq+J 400 mg QD+Pa 600 mg QD 20.50
Comparators from published literature
H*+R*+Z* (tested against MDR isolates) [8] 20.02









Drugs were tested by direct adding drugs directly to whole blood cultures of
healthy volunteers except for: * drugs were administered orally;
+ subjects were
TB patients. U=PNU-100480 600 mg BID; J=TMC207; Pa=PA-824;
H=isoniazid; R=rifampin; E=ethambutol; Z=pyrazinamide; L=levofloxacin.
The combination of PNU-100480, SQ109, and TMC207 400 mg QD was the most
active of those tested.
doi:10.1371/journal.pone.0030479.t002
Regimens for XDR-TB
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concentrations remain constant in each whole blood culture, post-
antibiotic effects (PAE) are not expressed; these might otherwise
prevent bacterial regrowth as drug levels fall below MIC in vivo.
However, sub-MIC concentrations of PNU-100840 and TMC207
are not anticipated for the regimens of greatest interest,
minimizing the significance of this shortcoming.
In summary, this study used a whole blood culture model to
examine potential novel drug combinations that might ultimately
be used to treat XDR-TB. The main findings were that
combinations including PNU-100480, TMC207, and SQ109
were highly active and fully additive, whereas those including
PA-824 were less than additive and in some instances antagonistic.
Further studies of the PNU-TMC combination are warranted.
The whole blood method can accelerate TB drug development.
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